Servier licenses Black Diamond’s RAS- and RAF-targeted drug
Black Diamond Therapeutics has found a buyer for an early-stage targeted cancer drug, which was brushed to the side last year as it focused resources on developing a next-generation lung cancer therapy. Servier will pay ...
Black Diamond Therapeutics has found a buyer for an early-stage targeted cancer drug, which was brushed to the side last year as it focused resources on developing a next-generation lung cancer therapy.
Servier will pay ...
